Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
LEAP THERAPEUTICS, INC. (LPTX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/12/2023 |
8-K
| Quarterly results |
| 06/09/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 05/25/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
8-K
| Quarterly results |
| 04/21/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/24/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/24/2023 |
8-K/A
| Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits Interactive Data |
| 03/24/2023 |
8-K
| Quarterly results |
| 03/24/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submiss...|
Docs:
|
"CERTIFICATE OF AMENDMENT TO CERTIFICATE OF DESIGNATION OF SPECIAL VOTING STOCK OF LEAP THERAPEUTICS, INC.",
"Option and License Agreement”), by and between Leap Therapeutics, Inc., a Delaware corporation , and BeiGene, Ltd., a Cayman Island exempted company incorporated with limited liability , that certain Clinical Manufacturing and Supply Agreement, dated as of April 23, 2020, by and between Leap and BeiGene, as amended, modified or supplemented from time to time prior to the date hereof , that certain Clinical Quality Agreement, dated as of May 3, 2020, by and between Leap and BeiGene, as amended, modified or supplemented from time to time prior to the date hereof , and that certain First Amended and Restated Pharmacovigilance Agreement, dated as of October 12, 2022, by and between Leap and BeiGene, as amended, modified or supplemented from time to time prior to the date hereof . The Option an...",
"Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01" |
|
| 03/13/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 6.8% stake in Leap Therapeutics, Inc. |
| 02/06/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 01/23/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/23/2023 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ...|
Docs:
|
"AGREEMENT AND PLAN OF MERGER",
"LEAP THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES X NON-VOTING CONVERTIBLE PREFERRED STOCK",
"THIS SUPPORT AGREEMENT , dated as of January 17, 2023, is made by and among Leap Therapeutics, Inc., a Delaware corporation , and HealthCare Ventures IX, L.P., a Delaware limited partnership (“Stockholder",
"Execution Version",
"REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement is made as of January 17, 2023, by and among Leap Therapeutics, Inc., a Delaware corporation , and those persons that as of the date of this Agreement become or have become entitled to receive Registrable Securities pursuant to, and in accordance with, the Merger Agreement and become parties to this Agreement by executing and delivering a counterpart signature page to this Agreement on the date of this Agreement or on any date thereafter . Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1 . RECITALS WHEREAS, pursuant to, and in accordance with, that certain Agreement and Plan of Merger, dated as of the date hereof, by and among the Company, Fir..." |
|
| 01/17/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/17/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/07/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 11/04/2022 |
8-K
| Quarterly results |
| 09/07/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/17/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/12/2022 |
8-K
| Quarterly results |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/12/2022 |
8-K
| Quarterly results |
| 06/16/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
8-K
| Quarterly results |
|
|
|